Sökning: WFRF:(Adamson Carly) >
Efficacy and Safety...
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide : Insights From the DAPA-HF Trial.
-
Butt, Jawad H. (författare)
-
Adamson, Carly (författare)
-
Docherty, Kieran F. (författare)
-
visa fler...
-
de Boer, Rudolf A. (författare)
-
Petrie, Mark C. (författare)
-
Inzucchi, Silvio E. (författare)
-
Kosiborod, Mikhail N. (författare)
-
Maria Langkilde, Anna (författare)
-
Lindholm, Daniel (författare)
-
Martinez, Felipe A. (författare)
-
Bengtsson, Olof (författare)
-
Schou, Morten (författare)
-
O’Meara, Eileen (författare)
-
Ponikowski, Piotr (författare)
-
Sabatine, Marc S. (författare)
-
Sjostrand, Mikaela (författare)
-
Solomon, Scott D. (författare)
-
Jhund, Pardeep S. (författare)
-
McMurray, John J. V. (författare)
-
Kober, Lars (författare)
-
visa färre...
- 2021
- 2021
- Engelska.
-
Ingår i: Circulation. Heart failure. ; 14:12
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Effective therapies for HFrEF usually reduce NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, and it is important to establish whether new treatments are effective across the range of NT- proBNP. METHODS: We evaluated both these questions in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial. Patients in New York Heart Association functional class II to IV with a left ventricular ejection fraction $<$/=40% and a NT-proBNP level $>$/=600 pg/mL ($>$/=600 ng/L; $>$/=400 pg/mL if hospitalized for HF within the previous 12 months or $>$/=900 pg/mL if atrial fibrillation/flutter) were eligible. The primary outcome was the composite of an episode of worsening HF or cardiovascular death. RESULTS: Of the 4744 randomized patients, 4742 had an available baseline NT-proBNP measurement (median, 1437 pg/mL [interquartile range, 857-2650 pg/mL]). Compared with placebo, treatment with dapagliflozin significantly reduced NT-proBNP from baseline to 8 months (absolute least-squares mean reduction, -303 pg/mL [95% CI, -457 to -150 pg/mL]; geometric mean ratio, 0.92 [95% CI, 0.88-0.96]). Dapagliflozin reduced the risk of worsening HF or cardiovascular death, irrespective of baseline NT-proBNP quartile; the hazard ratio for dapagliflozin versus placebo, from lowest to highest quartile was 0.43 (95% CI, 0.27-0.67), 0.77 (0.56-1.04), 0.78 (0.60-1.01), and 0.78 (0.64-0.95); P for interaction=0.09. Consistent benefits were observed for all-cause mortality. Compared with placebo, dapagliflozin increased the proportion of patients with a meaningful improvement ($>$/=5 points) in Kansas City Cardiomyopathy Questionnaire total symptom score (P for interaction=0.99) and decreased the proportion with a deterioration $>$/=5 points (P for interaction=0.87) across baseline NT-proBNP quartiles. CONCLUSIONS: In patients with HFrEF, dapagliflozin reduced NT-proBNP by 300 pg/mL after 8 months of treatment compared with placebo. In addition, dapagliflozin reduced the risk of worsening HF and death, and improved symptoms, across the spectrum of baseline NT-proBNP levels included in DAPA-HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Aged
- Atrial Fibrillation/drug therapy/physiopathology
- Benzhydryl Compounds/*adverse effects/*therapeutic use
- clinical trials
- Clinical Trials as Topic
- Glucosides/*adverse effects/*therapeutic use
- heart failure with reduced ejection fraction
- Heart Failure/*drug therapy/physiopathology
- Hospitalization/statistics & numerical data
- Humans
- Male
- Middle Aged
- Natriuretic Peptide
- Brain/*therapeutic use
- natriuretic peptides
- Peptide Fragments/*therapeutic use
- sodium-glucose cotransporter 2 inhibitors
- Stroke Volume/drug effects
- Ventricular Function
- Left/drug effects
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Butt, Jawad H.
-
Adamson, Carly
-
Docherty, Kieran ...
-
de Boer, Rudolf ...
-
Petrie, Mark C.
-
Inzucchi, Silvio ...
-
visa fler...
-
Kosiborod, Mikha ...
-
Maria Langkilde, ...
-
Lindholm, Daniel
-
Martinez, Felipe ...
-
Bengtsson, Olof
-
Schou, Morten
-
O’Meara, Eileen
-
Ponikowski, Piot ...
-
Sabatine, Marc S ...
-
Sjostrand, Mikae ...
-
Solomon, Scott D ...
-
Jhund, Pardeep S ...
-
McMurray, John J ...
-
Kober, Lars
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
- Circulation. Hea ...
- Av lärosätet
-
Uppsala universitet